Adenosine Kinase Deficiency: Report and Review

Alhanouf Alhusani¹ Abdulrahman Obaid¹ Henk J. Blom² Anna Wedell³,⁴,⁵,⁶ Majid Alfadhel¹

¹Division of Genetics, Department of Pediatrics, King Abdullah International Medical Research Centre, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Riyadh, Saudi Arabia
²Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
³Division of Metabolic Diseases, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden
⁴Department of Molecular Medicine and Surgery, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden
⁵Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden
⁶Max Planck Institute Biology of Ageing, Karolinska Institute Laboratory, Stockholm, Sweden

Address for correspondence Majid Alfadhel, MD, MHSC, FCCMG, Division of Genetics, Department of Pediatrics, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, PO Box 22490, Riyadh 11426, Saudi Arabia (e-mail: dralfadhelm@gmail.com).


Abstract

Adenosine kinase (ADK) deficiency (OMIM [online mendelian inheritance in man]: 614300) is an autosomal recessive disorder of adenosine and methionine metabolism, with a unique clinical phenotype, mainly involving the central nervous system and dysmorphic features. Patients usually present early in life with sepsis-like symptoms, respiratory difficulties, and neonatal jaundice. Subsequently, patients demonstrate hypotonia and global developmental delay. Biochemically, methionine is elevated with normal homocysteine levels and the diagnosis is confirmed through molecular analysis of the ADK gene. There is no curative treatment; however, a methionine-restricted diet has been tried with variable outcomes. Herein, we report a 4-year-old Saudi female with global developmental delay, hypotonia, and dysmorphic features. Interestingly, she has a tall stature, developmental dysplasia of the hip, optic nerve gliosis, and tigroid fundus. We found a mutation not reported previously and we compared the current case with previously reported cases. We alert clinicians to consider ADK deficiency in any neonate presenting with global developmental delay, hypotonia, dysmorphic features, and high methionine levels.

Keywords
► methionine
► ADK
► adenosine kinase deficiency
► adenosine
► inborn errors of methionine

Introduction

Adenosine kinase (ADK) deficiency (OMIM [online mendelian inheritance in man]: 614300) is an autosomal recessive inborn error of methionine and adenosine metabolism. It was first described by Bjursell et al in 2011 who reported two Swedish children with global developmental delay, hypermethioninemia, and liver impairment.¹ It is caused by a homozygous or compound heterozygous mutation in the ADK gene which encodes for the ADK enzyme.² The ADK enzyme is essential for the phosphorylation of adenosine to adenosine monophosphate.³ In addition, it removes adenosine which is critical for S-adenosylhomocysteine (AdoHcy) hydrolyase in methylation reactions, as it maintains S-adenosylmethionine (AdoMet) in trans methylation-dependent paths, where adenosine has to be continually removed.⁴ Under physiological status, adenosine is produced through the transmethylation of methionine, via AdoMet and AdoHcy. Subsequently, AdoHcy hydrolysis is achieved by S-AdoHcy hydrolyase to generate Hcy and adenosine.⁵ Hcy is remethylated again to methionine or irreversibly trans-sulfurated to cystine by cystathionine β-synthase, while

© 2019 Georg Thieme Verlag KG Stuttgart · New York
ISSN 0174-304X.
the adenosine is removed by deamination into inosine via adenosine deaminase (prenatally) and into adenosine monophosphate via phosphorylation (postnatally) by ADK.\textsuperscript{6,7} Accumulation of adenosine will cause elevated S-AdoHcy which is a strong inhibitor of most methylation reactions. Consequently, levels of S-AdoMet and methionine can become increased.

The clinical features of ADK deficiency include global psychomotor retardation/delay, muscular hypotonia, dysmorphic features (especially frontal bossing), mild to severe hepatic dysfunction, and epilepsy.\textsuperscript{1,2} Laboratory findings include high levels of liver enzymes, hyperbilirubinemia, hypermethioninemia, and elevated plasma AdoHcy and AdoMet. Neuroradiological abnormalities include brain atrophy, hydrocephalus, nonspecific white matter changes, and delayed myelination. Diagnosis requires the aforementioned clinical and biochemical abnormalities and confirmation through molecular analysis of the \textit{ADK} gene.\textsuperscript{1,2,5} There is no curative treatment. However, some previously reported cases were treated through a methionine-restricted diet and in addition to support the treatment, it included periodic monitoring of neurological and hepatic function, physiotherapy, occupational therapies, and long-term rehabilitation. These treatments resulted in variable outcomes.\textsuperscript{2,5} ADK deficiency has been reported in different countries including Sweden, Malaysia, Germany, and Iran. In the current report, we describe the first Saudi case of ADK deficiency, with optic nerve gliosis, tigroid fundus, and a tall stature that has not yet been associated with ADK deficiency. A novel frameshift duplication was found. We compare the presented case with the previously reported cases.

**Case Report**

The case concerns a 4-year-old female who is the fifth child of parents who are first cousins. She was born at 35 weeks of gestation through caesarean section because of preterm labor and a previous caesarean section with an Apgar's score 7 and 8 at 1 and 5 minutes, respectively. Her birth weight was 2.9 kg (75–90th percentile), length: 49 cm (75–90th percentile), and head circumference (HC): 33.5 cm (75–90th percentile). A few hours after birth, she developed tachypnoea, respiratory distress, and hypoactivity, and therefore was transferred to an Intermediate Care Nursery and was connected to a nasal cannula and treated using antibiotics and other supportive measures. On examination, she was found to be hypotonic with poor sucking and she developed jaundice. Therefore, the neurology department became involved and magnetic resonance imaging (MRI) of the brain showed delayed myelination and a left subependymal cyst. At this time, a metabolic genetics service became involved and the review for initial newborn screening was unremarkable. However, plasma amino acid levels at 18 days of life showed a high methionine level of 123 µmol/L (normal range 11–27 µmol/L) with a normal homocysteine level. The patient improved, and demonstrated spontaneous breathing, good sucking, weight gain, and tolerated feeding, and therefore was discharged after 1 month, with follow-up occurring in a clinic. At the age of 12 months, the patient was readmitted with poor feeding, decreased activity, fever (38.9°C), symptoms of an upper respiratory tract infection, and vomiting. Developmentally, she was bed-bound, with no head support. She was unable to sit or crawl (functioning as 2 months). Her weight was 9.5 kg (25th percentile), length 79 cm (95th percentile), and HC was 49 cm (> 95th percentile). She demonstrated subtle dysmorphic features (frontal bossing, high forehead, deep-seated eyes, and depressed nasal bridge; (\textsuperscript{→}Fig. 1). A neurological examination showed generalized hypotonia. The investigation also revealed persistent hypermethioninemia (methionine levels at approximately 1,500 µmol/L). The diagnosis of ADK deficiency was confirmed through whole-exome sequencing, (WES) which revealed a novel homozygous duplication in

**Fig. 1** DYSMORPHIC FEATURES AND BRAIN MRI FEATURES OF ADK DEFICIENCY. (A) An axial T2-weighted image shows delayed myelination. (B) Frontal bossing, high forehead, deep-seated eyes, and depressed nasal bridge. (C) An axial FLAIR image shows a small subependymal cyst at the left lateral ventricle. ADK, adenosine kinase; MRI, magnetic resonance imaging; FLAIR, fluid attenuated inversion recovery.
**Discussion**

Hypermethioninemia is a biochemical marker of inherited inborn errors of metabolism in the methylation pathway, such as methionine adenosyltransferase I/III (MAT I/III) deficiency, S-AdoHcy hydrolase (SAHH) deficiency, and cystathionine β-synthase (CBS) deficiency. And secondary due to, fumarylacetoacetate hydrolase (FAH) deficiency, citrin deficiency, and mitochondrial depletion syndrome caused by mutations in the **MPV17** and **DGUOK** genes. The most common cause of hypermethioninemia is liver disease, next to low birth weight and prematurity.

> Table 1 summarizes the clinical characteristic of previously reported patients with ADK deficiency, including the current case. To date, 19 cases have been reported in the literature. ADK deficiency is pan-ethnic. Patients from Sweden, Malaysia, Turkey, Kuwait, Italy, Morocco, Germany, and Iran have been reported. The current report details the first Saudi patient to date. A total of 90% of cases present in the neonatal period, indicating an early onset with sepsis-like symptoms, hypoglycemia, and neonatal jaundice in 84% of patients. All patients demonstrate global developmental delay, frontal bossing, and hypotonia. The most common phenotype includes dysmorphic features in the form of frontal bossing, deep-seated eyes, hypertelorism, a high forehead, a depressed nasal bridge, thin sparse hair, and slender hands and feet. Macrocephaly is found in at least half of patients. Seizure presents in approximately 68% of cases, and the type is nonspecific consisting of both partial and generalized epilepsy with a variable age of onset. Haplotypological signs consist of elevated transaminases (90%) and hepatic fibrosis (32%), while hepatomegaly was found in only one patient. Cardiac defects, including pulmonary stenosis, atrial septal defects, coarctation of the aorta, ventricular septal defects, and patent ductus arteriosus, have been reported. Interestingly, the current case showed no hepatomegaly, hepatic fibrosis, or seizures. Approximately 60% of patients suffer from failure to thrive and short stature but the presented case demonstrates tall stature. Other features present in a few cases include strabismus, undescended testis, retinal dystrophy, abnormal dentition, cholelithiasis, neurogenic bladder, and megaloblastic anemia. The present patient differs from the previously reported cohort through the findings of developmental dysplasia of the hip, optic nerve gliosis, and tigroid fundus. These findings expand the phenotype of ADK deficiency.

The ADK gene has been mapped to chromosome 10q22.2, spans approximately 550 kb of genomic DNA, and consists of 11 exons. The mutation spectrum of ADK deficiency is extremely heterogeneous. The most common type is missense mutation (50%). Other variations include deletion, nonsense, and deletion–insertion mutations. This is the first report of a duplication creating a frameshift starting at codon Asn272 and ending in a stop codon 15bp downstream. This variant is not described in the Exome Aggregation Consortium, Exome Sequencing Project, or 1,000 genomes browser, as well as a database of 2000 in-house ethnically matched xomes supports its pathogenicity. In ADK deficiency, there appears to be no clear genotype–phenotype correlation.

Since methionine is elevated in this disorder, substrate reduction therapy through a methionine-restricted diet (MRD) may be reasonable and 42% of the cohort was treated through an MRD with variable efficacy. In several patients, an...
An improvement in cognitive function, developmental delays, and speech were reported while in others treatment was ineffective. The current patient was not treated through an MRD. However, methionine levels decreased spontaneously over the past 2 years. The early onset of ADK deficiency in the first few days of life indicates that the pathology may start in utero and this may explain why MRD has been largely ineffective in this disorder.

Table 1  Summary of the clinical characteristics of previously reported patients with ADK deficiency compared with the current case

<table>
<thead>
<tr>
<th>Authors</th>
<th>Bjursell et al, 2011</th>
<th>Staufner et al, 2016</th>
<th>Shakiba et al, 2016</th>
<th>Current study, 2018</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases</td>
<td>6</td>
<td>11</td>
<td>1</td>
<td>1</td>
<td>19</td>
</tr>
<tr>
<td>Male:female</td>
<td>4:2</td>
<td>4:7</td>
<td>0:1</td>
<td>0:1</td>
<td>8:11</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Two Swedish and four Malaysian</td>
<td>Four Turkish, two Kuwaiti, one Italian, one Moroccan, one German, two Iranian</td>
<td>Iranian</td>
<td>Saudi</td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis (y)</td>
<td>8–24</td>
<td>1.9–29</td>
<td>3</td>
<td>1</td>
<td>1–24</td>
</tr>
<tr>
<td>Neonatal onset</td>
<td>6/6</td>
<td>9/11</td>
<td>+</td>
<td>+</td>
<td>17/19 (90)</td>
</tr>
<tr>
<td>Developmental delay</td>
<td>6/6</td>
<td>11/11</td>
<td>+</td>
<td>+</td>
<td>19/19 (100)</td>
</tr>
<tr>
<td>Frontal bossing</td>
<td>6/6</td>
<td>11/11</td>
<td>+</td>
<td>+</td>
<td>19/19 (100)</td>
</tr>
<tr>
<td>Hypotonia</td>
<td>6/6</td>
<td>11/11</td>
<td>+</td>
<td>+</td>
<td>19/19 (100)</td>
</tr>
<tr>
<td>Seizure</td>
<td>6/6</td>
<td>7/11</td>
<td>–</td>
<td>–</td>
<td>13/19 (68)</td>
</tr>
<tr>
<td>Neonatal jaundice</td>
<td>5/6</td>
<td>9/11</td>
<td>+</td>
<td>+</td>
<td>16/19 (84)</td>
</tr>
<tr>
<td>Elevated transaminases</td>
<td>6/6</td>
<td>9/11</td>
<td>+</td>
<td>+</td>
<td>17/19 (90)</td>
</tr>
<tr>
<td>Hepatic fibrosis</td>
<td>1/6</td>
<td>4/11</td>
<td>+</td>
<td>–</td>
<td>6/19 (32)</td>
</tr>
<tr>
<td>Hepatomegaly</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>1/19 (5)</td>
</tr>
<tr>
<td>Hypertelorism</td>
<td>6/6</td>
<td>7/11</td>
<td>+</td>
<td>+</td>
<td>17/19 (90)</td>
</tr>
<tr>
<td>Sparse, thin hair</td>
<td>–</td>
<td>4/11</td>
<td>+</td>
<td>–</td>
<td>5/19 (26)</td>
</tr>
<tr>
<td>Short stature and FTT</td>
<td>6/6</td>
<td>5/11</td>
<td>–</td>
<td>–</td>
<td>11/19 (58)</td>
</tr>
<tr>
<td>Cardiac defect</td>
<td>3/6</td>
<td>5/11</td>
<td>+</td>
<td>–</td>
<td>9/19 (47)</td>
</tr>
<tr>
<td>Sensorineural hearing loss</td>
<td>2/6</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2/19 (10)</td>
</tr>
<tr>
<td>Methionine restricted diet</td>
<td>–</td>
<td>7/11</td>
<td>+</td>
<td>–</td>
<td>8/19 (42)</td>
</tr>
<tr>
<td>Prognosis</td>
<td>One patient died at 10 y after a refractory seizure. The others survived until adulthood with global developmental delay</td>
<td>One patient died at 15 mo. The others survived and some reached adulthood with global developmental delay</td>
<td>Global developmental delay</td>
<td>Global developmental delay</td>
<td></td>
</tr>
<tr>
<td>Other features</td>
<td>Macrocephaly in 5/6. Slender hands and feet</td>
<td>Undescended testis, strabismus, retinal dystrophy, abnormal dentition, cholelithiasis, MA, slender hands and feet</td>
<td>Recurrent infection, neurogenic bladder, megaloblastic anemia</td>
<td>Macrocephaly, tall stature, optic nerve glioma, tigroid fundus, developmental dysplasia of the hips, lax joint, slender hands and feet</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: ADK, adenosine kinase; FTT, failure to thrive; MA, megaloblastic anemia.
Two patients died in the reported cohort, while the others survived into the third decade, demonstrating that this disorder is generally not lethal and patients can live but with global developmental delay.

**Conclusion**

We expand the phenotype of ADK deficiency to include tall stature, developmental dysplasia of the hip, optic nerve gliosis, and tigroid fundus. We have reported a novel mutation, and we compared the current case with previously reported cases. ADK deficiency consists of a triad of global developmental delay, hypotonia, and frontal bossing. Macrocephaly and hypertelorism are common findings; and this disease has a variable degree of hepatic and cardiac features, and early onset of the disease is characteristic. Moreover, international registries such as E-HOD (European Network and Registry for Homocystinurias and Methylation Defects; http://www.e-hod.org/), which document more cases of the ADK gene defect, will lead to a better understanding of the natural history of this inborn error of metabolism and facilitate well-designed, large-sample clinical trials which may aid in improving the management of this genetic disorder.

**Author Contributions**

A.A.: wrote the first draft and edited the subsequent version of the manuscript.

A.O.: collected the clinical data and edited the manuscript.

A.W.: edited the manuscript and reviewed the clinical data.

H.J.B.: edited the manuscript and reviewed the clinical data.

M.A.: supervised the work associated with preparing, writing, and submitting the manuscript and contributed to the clinical diagnosis and management of the patient.

All authors have read and approve the final draft of the manuscript.

**Conflict of Interests**

None.

**Funding Sources**

No funding for this article from any institution or agency.

**Ethics Approval and Consent to Participate**

This study was approved by the institutional review board office at King Abdullah International Medical Research Centre (KIMARC; study number: RC16/113/R).

**Consent for Publication**

Written consent was obtained from the parents.

**Acknowledgments**

We are grateful to the patient and her family for their genuine support.

**References**


